1.1 Pemetrexed is not recommended for the maintenance treatment of locally advanced or metastatic non‑squamous non‑small‑cell lung cancer (NSCLC) in people whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.
1.2 People currently receiving treatment initiated within the NHS with pemetrexed that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.